Saturday, 21 September 2019

Sabinsa’s Lactospore receives positive response

09 January 2019 | News

The authors noted that LactoSpore showed remarkable immunomodulatory and anti-inflammatory activity under co-treatment relative to post-treatment condition.

A  recent  peer-reviewed  study  reported  the  results  of  an investigation  into  the  functional  aspects  of  Sabinsa’s  shelf  stable  probiotic Bacillus coagulans MTCC 5856,  known  worldwide  as  LactoSpore®,   including  survival  during  simulated  digestion.  The  study,  Probiotic Bacillus coagulans MTCC 5856 spores exhibit excellent in-vitro functional efficacy in simulated gastric survival, mucosal adhesion and immunomodulation, was published in the Journal of Functional Foods (2019 Jan; 52: 100-108).

This   independent   study   conducted   by   university   researchers   reported   that LactoSpore showed remarkable ability to survive (92%) gastric and intestinal conditions and then to colonize the intestine by effectively adhering to the colonic epithelium. 

Furthermore, this study also reported that LactoSpore at a dose of 2×109 cfu/ml did not show any cytotoxic effects towards HT-29 or LS174T cells, adding to the scientific evidence of safety previously demonstrated by several clinical trials. 

LactoSpore exhibited excellent immunomodulatory efficacy by down regulating the secretion of the IL-8 (key  pro-inflammatory  cytokine)  while  concomitantly  promoting  increased  secretion  of  IL-10  (anti- inflammatory cytokine). 

The authors also noted that LactoSpore showed remarkable immunomodulatory and anti-inflammatory activity under co-treatment relative to post-treatment condition suggesting significance of early application in order to suppress inflammation and support its incorporation into functional foods for improved gut health. 

The prominent survival during digestion, adhesion capacity and remarkable immunomodulatory potential of LactoSpore, coupled with its known ability to survive the food processing conditions and storage, supports its incorporation into shelf stable food products targeted at improving and/or treating gut health,” said Sami-Sabinsa founder Dr. Muhammed Majeed.

LactoSpore is Sabinsa’s clinically validated and commercial probiotic preparation containing L (+) lactic acid producing microbial preparation from Bacillus coagulans MTCC 5856. Sabinsa offers LactoSpore at various  strengths:  6  billion,  15  billion  and  100  billion  spores/g.  The  health  benefits  and  stability  of LactoSpore  have  been  published  in  multiple  peer-reviewed  journals,  and  the  present  investigation  further   supports   the   functional   benefits   of   this   branded   probiotic   in   human   health.  

Loading...

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account